Sandbox Reserved 687
From Proteopedia
(Difference between revisions)
| Line 3: | Line 3: | ||
<!-- PLEASE ADD YOUR CONTENT BELOW HERE --> | <!-- PLEASE ADD YOUR CONTENT BELOW HERE --> | ||
| - | + | =Complera: Emtricitabine/rilpivirine/tenofovir= | |
* Marketed by: Gilead Sciences and Janssen Therapeutics | * Marketed by: Gilead Sciences and Janssen Therapeutics | ||
* Major Indication: [[HIV]] infection | * Major Indication: [[HIV]] infection | ||
| - | * Drug Class: Combination of nucleoside/tide [[reverse transcriptase]] inhibitor and nonnucleoside [[reverse transcriptase]] inhibitor | + | * Drug Class: Combination of [[nucleoside]]/tide [[reverse transcriptase]] inhibitor and nonnucleoside [[reverse transcriptase]] inhibitor |
* Date of FDA Approval: August 2011 | * Date of FDA Approval: August 2011 | ||
| + | Upon infection, [[HIV]] binds to the [[CD4]] receptor in a helper T cell or other CD4-presenting [[lymphocyte]]. The viral envelope is then fused with the cellular membrane allowing intracellular release of viral particles. The utilization of several enzymes helps to solidify the virus’s hold on the cell. HIV [[reverse transcriptase]] (RT) works to convert the viral single-stranded [[RNA]] (ssRNA) into [[DNA]]. HIV [[integrase]] then helps to incorporate the newly reverse transcribed DNA into the cellular genome. (Voet et al. 2008) | ||
| - | + | ==[[Rilpivirine]] (RPV)== | |
| - | =Rilpivirine (RPV)= | + | |
<Structure load='4I2P' size='500' frame='true' align='right' caption='Crystal structure of HIV-1 reverse transcriptase in complex with rilpivirine' scene='Insert optional scene name here' /> | <Structure load='4I2P' size='500' frame='true' align='right' caption='Crystal structure of HIV-1 reverse transcriptase in complex with rilpivirine' scene='Insert optional scene name here' /> | ||
| Line 20: | Line 20: | ||
<scene name='Sandbox_Reserved_687/Rvp_in_nnrbi_of_p66/1'>NNRTI binding pocket</scene> In red are the binding pocket residues p66 (Leu-100, Lys-101, Lys-103, Val-106, Thr-107, Val-108, Val-179, Tyr-181, Tyr-188, Val-189, Gly-190, Phe-227, Trp-229, Leu- 234, and Tyr-318) and p51(Glu-138). Singh et al. | <scene name='Sandbox_Reserved_687/Rvp_in_nnrbi_of_p66/1'>NNRTI binding pocket</scene> In red are the binding pocket residues p66 (Leu-100, Lys-101, Lys-103, Val-106, Thr-107, Val-108, Val-179, Tyr-181, Tyr-188, Val-189, Gly-190, Phe-227, Trp-229, Leu- 234, and Tyr-318) and p51(Glu-138). Singh et al. | ||
| - | Tenofovir | + | [[Tenofovir]] |
[[Image:Tenofovir.png]] | [[Image:Tenofovir.png]] | ||
| Line 28: | Line 28: | ||
<scene name='Sandbox_Reserved_687/Rt_with_palm_structure_labels/2'>p66 and TFV</scene> | <scene name='Sandbox_Reserved_687/Rt_with_palm_structure_labels/2'>p66 and TFV</scene> | ||
| - | Emtricitabine | + | [[Emtricitabine]] |
[[Image:Emtricitabine3.png]] | [[Image:Emtricitabine3.png]] | ||
<Structure load='Insert PDB code or filename here' size='500' frame='true' align='right' caption='Insert caption here' scene='Insert optional scene name here' /> | <Structure load='Insert PDB code or filename here' size='500' frame='true' align='right' caption='Insert caption here' scene='Insert optional scene name here' /> | ||
Revision as of 20:47, 2 May 2013
| This Sandbox is Reserved from 30/01/2013, through 30/12/2013 for use in the course "Biochemistry II" taught by Hannah Tims at the Messiah College. This reservation includes Sandbox Reserved 686 through Sandbox Reserved 700. |
To get started:
More help: Help:Editing |
Complera: Emtricitabine/rilpivirine/tenofovir
- Marketed by: Gilead Sciences and Janssen Therapeutics
- Major Indication: HIV infection
- Drug Class: Combination of nucleoside/tide reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor
- Date of FDA Approval: August 2011
Upon infection, HIV binds to the CD4 receptor in a helper T cell or other CD4-presenting lymphocyte. The viral envelope is then fused with the cellular membrane allowing intracellular release of viral particles. The utilization of several enzymes helps to solidify the virus’s hold on the cell. HIV reverse transcriptase (RT) works to convert the viral single-stranded RNA (ssRNA) into DNA. HIV integrase then helps to incorporate the newly reverse transcribed DNA into the cellular genome. (Voet et al. 2008)
Rilpivirine (RPV)
|
RPV in the In red are the binding pocket residues p66 (Leu-100, Lys-101, Lys-103, Val-106, Thr-107, Val-108, Val-179, Tyr-181, Tyr-188, Val-189, Gly-190, Phe-227, Trp-229, Leu- 234, and Tyr-318) and p51(Glu-138). Singh et al.
|
Reverse Transcriptase:
Emtricitabine Image:Emtricitabine3.png
|
